PEG-Conjugated Alcohol Dehydrogenase for Ethanol Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for accelerating ethanol elimination from the body, such as enzyme systems, face challenges like gastric pH deactivation, proteolytic degradation, and hyperosmolar conditions, making them impractical for commercial use in reducing blood alcohol levels effectively.
Innovation Solution
A pharmaceutical composition comprising a protein with an amino acid sequence encoding alcohol dehydrogenase (ADH) or KRED, bound to a long-acting molecule, which is administered to subjects to lower blood alcohol levels by enhancing the enzyme's longevity and potency, thereby increasing its ability to oxidize ethanol efficiently.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional enzyme systems are used to accelerate ethanol elimination, then the elimination rate increases, but the enzymes are deactivated by gastric pH and undergo proteolytic degradation
Solution Approach 1:
The patent modifies the enzyme's molecular structure through site-specific conjugation with polyethylene glycol (PEG) chains, changing its physical and chemical parameters to achieve pH resistance and protease protection while maintaining catalytic activity. This structural modification allows the enzyme to function reliably in the harsh gastric environment.
Solution Approach 2:
The patent creates a composite enzyme construct by covalently attaching PEG chains to specific residues on the enzyme surface. This composite structure combines the catalytic functionality of the original enzyme with the protective and stabilizing properties of PEG, resulting in an enzyme that is resistant to pH extremes and proteolytic degradation.
2Productivity
If multi-enzyme systems with substrate pumped NAD recycling are used, then ethanol metabolism is enhanced, but the system creates hyperosmolar conditions
Solution Approach 1:
The patent extracts and eliminates the problematic NAD recycling components from the enzyme system, relying instead on the endogenous NADH regeneration capacity of the liver. This simplifies the system to a single enzyme component, avoiding the hyperosmolar conditions created by high concentrations of buffer salts, substrates, and cofactors required for external NAD recycling.
Solution Approach 2:
The patent enables the enzyme system to utilize the body's own endogenous NADH regeneration mechanisms rather than requiring external NAD recycling systems. The modified ADH enzyme works with the liver's natural metabolic pathways, allowing the body to self-regulate the cofactor balance without introducing hyperosmolar substances.
3Reliability
If high concentrations of buffer salts and cofactors are used to maintain enzyme activity, then enzyme stability improves, but the system becomes hyperosmolar and impractical for commercial use
Solution Approach 1:
The patent changes the enzyme's intrinsic properties through PEG conjugation, transforming it from a labile protein requiring high concentrations of stabilizing agents to a robust enzyme that maintains activity in physiological conditions. This eliminates the need for hyperosmolar buffer systems and makes the product commercially viable.
Solution Approach 2:
The patent creates a stable, long-lasting enzyme product that does not require continuous supplementation of expensive cofactors or buffer salts. The PEG-modified enzyme maintains its activity throughout the elimination process without degradation, eliminating the need for complex, expensive multi-component systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively lowers blood alcohol levels and prevents alcohol-related symptoms by maintaining elevated enzyme activity and reducing the risk of alcohol poisoning, providing a practical means for rapid ethanol metabolism.
Implementation Method 1
ADH has many roles in the body; a major function is to catalyze the oxidation of ethanol (EtOH) to acetaldehyde
Implementation Method 2
Alcohol Dehydrogenase (ADH) refers to a family of enzymes which catalyze the reversible oxidation of primary or secondary alcohols to aldehydes or ketones
Data Source
AI summary
The present invention provides a pharmaceutical composition containing 10 mg to about 100 g KRED and/or a long-acting alcohol dehydrogenase as an active ingredient and a pharmaceutically acceptable carrier. Moreover, provided herein methods for lowering blood alcohol level, methods for preventing a symptom or a risk arising from alcohol consumption and methods for treating a subject afflicted with alcoholism by the administration of the pharmaceutical composition of the invention.